Clinical
Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study
Summary
This retrospective study investigated prognostic factors and outcomes of postmastectomy radiation therapy (PMRT) following neoadjuvant chemotherapy (NAC) and mastectomy for stage II-III breast cancer. It included 178 patients with a median follow-up of 64 months. The findings indicated that response to NAC, molecular subtype, and pathologic stage are independent predictors of treatment outcomes. PMRT did not offer significant benefits for patients with pathologically node-negative disease (ypN0) but significantly improved locoregional control, progression-free survival, and overall survival in those with residual lymph nodes (ypN1-3). Triple-negative subtype and non-response to NAC were identified as poor prognostic factors.
Critical appraisal
This retrospective cohort study, with a median follow-up of 64 months, provides significant evidence to refine the indications for postmastectomy radiation therapy (PMRT) after neoadjuvant chemotherapy (NAC) for breast cancer. It identifies residual pathologic lymph nodal status (ypN1-3) as a key predictive biomarker for PMRT benefit, showing significant improvements in locoregional control (P< .01), progression-free survival (P< .01), and overall survival (P = .02) in this subgroup. Conversely, PMRT showed no benefit for ypN0 patients. These findings suggest that current clinical guidelines could be revised to better target PMRT, potentially avoiding unnecessary treatment in ypN0 patients and reinforcing it in ypN1-3 cases. The clinical impact could be seen within 1-3 years, justifying prospective trials or meta-analyses to validate these observations and change practice.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology